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INTRODUCTION
Hypertension is a key risk factor for the 
development of cardiovascular disease 
(CVD),1 the major cause of morbidity and 
mortality worldwide.2 Classifications of 
hypertension are, by definition, arbitrary 
and, although most guidelines now 
include consideration of underlying CVD 
risk, many recommend pharmacological 
treatment of blood pressure when it is 
sustained at ≥140/90 mmHg, regardless of 
the underlying risk, end organ damage, 
diabetes, or history of CVD (Table 1).3–13
The treatment of uncomplicated (that 
is, low risk of CVD) stage 1 hypertension 
(sustained blood pressure of 140/90–
159/99 mmHg) has long been considered 
controversial due to the paucity of 
evidence to support such a strategy.14–17 
A recent Cochrane Review18 examined 
8912 patients from four clinical trials and 
found no significant reduction in mortality 
or cardiovascular events with treatment. 
Despite these data, new international 
guidelines and pay-for-performance 
indicators continue to recommend 
treatment.3,4,19 Only guidelines in the UK, 
Australia, and New Zealand recommend 
lifestyle advice rather than pharmacological 
interventions for uncomplicated stage 1 
hypertension (Table 1).10–12
The impact of these recommendations 
on clinical practice is unclear. Although 
the prevalence of hypertension is well 
documented across the world,20–24 few 
studies have examined the prevalence of 
stage 1 hypertension25,26 and none, to the 
authors’ knowledge, have examined its 
prevalence with regard to CVD risk. This 
study aimed to establish the total number of 
individuals potentially requiring treatment 
for uncomplicated stage 1 hypertension, 
according to international guidelines, in a 
typical UK primary care population. These 
estimates were extrapolated to national 
data27 and the cost impact of achieving 
blood pressure control was quantified in 
this population using published costs.28,29
METHOD
Data collection
A cross-sectional retrospective study of 
anonymised, primary care medical records 
was conducted in 19 general practices 
across the West Midlands, UK. The methods 
of data collection have been detailed 
elsewhere.30,31 Briefly, relevant data were 
extracted from patient medical records 
using MIQUEST software. All data queries 
were run between 17 October 2008 and 
6 October 2009; extracted data included: 
• demographic information; 
• cardiovascular risk-factor details; and 
• all cholesterol and blood pressure 
lowering medication prescribed within 
the 90 days prior to the query date. 
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Treatment for uncomplicated stage 1 
hypertension is recommended in most 
international guidelines but there is little 
evidence to indicate that therapy is beneficial.
Aim
To estimate the prevalence of this condition 
in an untreated population and the potential 
costs of initiating therapy in such patients.
Design and setting
Cross-sectional study of anonymised patient 
records in 19 general practices in the West 
Midlands, UK.
Method
Data relating to patient demographics, existing 
cardiovascular disease (CVD), and risk factors 
(blood pressure and cholesterol) were extracted 
from patient records. Patients with a blood 
pressure of 140/90–159/99 mmHg, no CVD, 
and <20% 10-year cardiovascular risk were 
classified as having uncomplicated stage 1 
hypertension. Missing data were imputed. The 
prevalence of untreated, uncomplicated stage 1 
hypertension was estimated using descriptive 
statistics and extrapolated using national data. 
The cost of achieving blood pressure control in 
this population was examined in a cost–impact 
analysis using published costs from previous 
studies.
Results
Of the 34 975 patients (aged 40–74 years) in 
this study, untreated, uncomplicated stage 1 
hypertension was present in 2867 individuals 
(8.2%, 95% confidence interval [CI] = 7.9 to 
8.5). This is equivalent to 1 892 519 patients in 
England and Wales, for whom the additional 
cost of controlling blood pressure, according to 
guidelines, was estimated at £106–229 million 
per annum, depending on the health 
professional delivering care.
Conclusion
Untreated, uncomplicated stage 1 hypertension 
is relatively common, affecting 1 in 12 patients 
aged 40–74 years in primary care. Current 
international guidelines and pay-for-performance 
targets, if followed, will incur significant costs for 
a patient benefit that is debatable.
Keywords
antihypertensive agents; cardiovascular disease 
risk; guidelines; primary prevention.
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Prevalence and costs of treating uncomplicated 
stage 1 hypertension in primary care:
a cross-sectional analysis
This study focused on individuals aged 
40–74 years, as younger people require 
further assessment for secondary causes 
of hypertension before treatment is 
administered12 and older individuals are 
likely to fall into the high CVD risk group and, 
therefore, not be relevant to the research 
questions addressed here. 
Definition of uncomplicated stage 1 
hypertension
This study aimed to establish the 
prevalence of untreated, uncomplicated 
stage 1 hypertension. As such, patients 
with no blood pressure reading from the 
preceding 5 years, those with existing CVD, 
or those already receiving blood pressure 
or cholesterol-lowering therapy were not 
considered in this analysis; it was assumed 
that patients receiving blood pressure- or 
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Table 1. Summary of treatment recommendations for patients with stage 1, 2, and 3 hypertension
 Low CVD risk High CVD riska
 Country/  Stage 1 Stage 2 Stage 3 Stage 1 Stage 2 Stage 3 
Guideline region Year HT HT HT HT HT HT Notes
European Society of Europe 2013 Therapy Therapy Therapy Therapy Therapy Therapy Initiate therapy in low-risk stage 1 HT 
Hypertension3         if lifestyle modification is unsuccessful
Canadian Hypertension Canada 2013 Therapy Therapy Therapy Therapy Therapy Therapy Therapy should only be initiated if mean 
Education Program4         BP is raised on three occasions (high 
         risk or stage 2–3 HT) or five occasions 
         (stage 1 HT and low risk)
National Institute for UK 2011 Lifestyle Therapy Therapy Therapy Therapy Therapy Diagnosis of hypertension is based on 
Health and Care   advice      a combination of clinic and ambulatory 
Excellence12         BP readings
National Heart Australia 2010 Lifestyle Lifestyle Therapy Therapy Therapy Therapy Treatment is also recommended in 
Foundation of   advice advice     patients with moderate CVD risk 
Australia11         (10–15%) and raised BP (>140/90 mmHg)
Latin American Society Latin America 2009 Therapy Therapy Therapy Therapy Therapy Therapy Therapy should only be initiated in 
of Hypertension7          patients with stage 1 or 2 HT if raised 
         BP persists for ‘a few weeks’ (in those 
         with moderate CVD risk) or ‘several 
         months’ (in those with low CVD risk)
Japanese Society of Japan 2009 Therapy Therapy Therapy Therapy Therapy Therapy Therapy should be initiated in patients 
Hypertension9         with stage 1 HT if raised BP is 
         sustained after a period of lifestyle 
         modification
American Heart US 2006–2014 Therapy Therapy Therapy Therapy Therapy Therapy JNC8 suggests patients aged ≥60 years 
Association5,6,13         should only be treated if BP is 
         ≥150/90 mmHg
New Zealand New Zealand 2003 Lifestyle Lifestyle Therapy Therapy Therapy Therapy Treatment is based solely on CVD risk:  
Guidelines Group10   advice advice     those with high CVD risk should receive 
         therapy. Stage 3 HT = ≥170/100 mmHg
WHO/International World 2003 Therapy Therapy Therapy Therapy Therapy Therapy 
Society of Hypertension8
aIncludes estimated CVD risk ≥20%, existing CVD, diabetes, renal disease, and target organ damage. Stage 1 hypertension = 140/90–159/99 mmHg; stage 2 hypertension 
= 160/100–179/109 mmHg; stage 3 hypertension = ≥180/110 mmHg. BP = blood pressure. CVD = cardiovascular disease. HT = hypertension. JNC8 = Eighth Joint National 
Committee. WHO = World Health Organization.
How this fits in
There are varying recommendations on 
how to treat people with uncomplicated 
stage 1 hypertension, but many guidelines 
recommend therapy for all whose blood 
pressure is ≥140/90 mmHg, despite 
the lack of robust clinical trial evidence 
supporting treatment. At least 1 in 12 
patients aged 40–74 years old have the 
condition but receive no treatment for it. 
The cost of initiating treatment in these 
individuals in England and Wales in line 
with current international guidelines, 
would be substantial (£106–229 million: 
US$180–389 million and €134–289 million) 
in the first year, but the benefits for 
patients are unknown. 
cholesterol-lowering therapy had been 
at high risk of CVD prior to initiation.12,32 
The remaining patients formed a potential 
primary-prevention population and were 
subdivided on the basis of blood pressure 
level (<140/90 mmHg = normotension; 
140/90–159/99 mmHg = stage 1 
hypertension; ≥160/100 mmHg = stage 2–3 
hypertension) and CVD risk score. 
Given that the classification of 
hypertension was based on only the most 
recent clinic blood pressure reading, the 
prevalence of stage 1 hypertension was 
adjusted to account for the 56% positive 
predictive value (PPV) of clinic blood 
pressure measurements around the 
diagnostic threshold for hypertension.33 The 
prevalence of stage 2–3 hypertension was 
not adjusted due to uncertainty about the 
PPV of blood pressure measurement at 
higher levels. No attempt was made to 
impute missing blood pressure data.
Definition of cardiovascular risk status
Where possible, data on cardiovascular 
risk factors were used to estimate CVD 
risk using the Framingham equation.34 
This risk calculator was recommended by 
the National Institute for Health and Care 
Excellence (NICE)35 at the time of data 
collection; it is now recognised, however, 
that other risk calculators36 may be more 
appropriate for use in UK populations.32 
CVD risk scores were adjusted by a factor 
of 1.4 or 1.5 for patients of South Asian 
origin or a family history of premature 
cardiovascular events respectively.35 Where 
total or high-density lipoprotein (HDL) 
cholesterol information was not available, 
values were imputed using the observed 
mean cholesterol for patients of the same 
sex and age group (5-year age bands) with 
existing cholesterol readings. All other risk 
factors were assumed not to be present if 
they were absent from the patient medical 
records. 
Estimation of costs
The potential costs of treating 
uncomplicated stage 1 hypertension were 
examined in a cost–impact analysis using 
the methodology utilised by NICE for the 
development of costing tools to assist the 
implementation of new guidance.37 This 
methodology uses data describing the 
affected population, the required activity, 
and the cost of that activity to estimate 
the financial impact of implementing new 
guidance on health service budgets. It does 
not consider these costs in the context of 
quality-adjusted life years gained, as is the 
case in a health economic analysis. 
The level of new activity generated by 
guideline implementation was defined 
in the present study as the number of 
drugs required to control blood pressure 
to <140/90 mmHg in each patient and the 
health professional’s time incurred when 
prescribing and monitoring the treatment 
regimen. These figures were estimated 
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Table 2. Unit costs of treatment and NHS service delivery required to achieve blood pressure control in 
patients with uncomplicated stage 1 hypertension
 Annual cost per patient, £
  Patients requiring Patients requiring Patients requiring Patients requiring 
Cost type Cost per unit, £ no drugs one drug two different drugs  three different drugs
Drugsa 
  Amlodipine 10 mg (28-tablet pack) 1.07 (1 pack) 0 13.96 27.92 41.87 
  Ramipril 10 mg (28-capsule pack) 1.30 (1 pack) 0 16.96 33.92 50.87 
  Indapamide 2.5 mg (28-tablet pack) 1.40 (1 pack) 0 18.26 36.53 54.79 
  Total treatment for a patient aged <55 yearsb - 0 16.96 30.92 49.18 
  Total treatment for a patient aged ≥55 yearsb - 0 13.96 30.92 49.18
Service deliveryc,d 
  Practice nurse 45/hour 11.25 22.50 33.75 45.00 
  Nurse specialist 81/hour 20.25 40.50 60.75 81.00 
  GP 185/hour 36.00 72.00 108.00 144.00
Total cost of treatment (aged ≥55 years) 
  Drug + practice nurse - 11.25 36.46 64.67 94.18 
  Drug + nurse specialist - 20.25 54.46 91.67 130.18 
  Drug + GP  - 36.00 85.96 138.92 193.18
aCosts taken from NHS Electronic Drug Tariff database, correct as of May 2013.28 bAs defined by the National Institute for Health and Care Excellence treatment algorithm.  
cCosts of service delivery given per consultation (unless otherwise stated) based on a face-to-face, 15-minute nurse consultation or a 11.7-minute GP consultation. dCosts taken 
from Unit Costs of Health and Social Care 2012.29
Table 3. Characteristics of the 
study population, n = 34 975
Characteristic n (%)a
Female 16990 (49) 
Age, mean (SD) 54 (± 10) 
South Asian ethnicity 1899 (12)b 
Family history of CVD 4213 (12) 
Diabetes 2598 (7) 
Left ventricular hypertrophy 77 (0) 
Chronic kidney disease 1302 (4) 
Myocardial infarction 733 (2) 
Peripheral vascular disease 487 (1) 
Heart failure 253 (1) 
Ischaemic heart disease 1678 (5) 
Stroke 331 (1) 
Transient ischaemic attack 295 (1)
aUnless otherwise stated. bPercentage of 15 825  
patients in whom ethnicity was recorded. Ethnicity 
is typically collected by self-report at registration; 
the relatively low proportions recorded reflect 
patients who have been registered for some years. 
CVD = cardiovascular disease. SD = standard  
deviation.
Figure 1. Prevalence of hypertension by age and sex.
using data from the Hypertension Optimal 
Treatment trial.38 Drug choice was guided 
by the NICE treatment algorithm, which 
recommends different combinations of 
therapy according to patient age and ethnic 
group.12
The costs of resource utilisation were 
estimated using the NHS Electronic Drug 
Tariff 28 (cost of drug prescription) and Unit 
Costs of Health and Social Care 2012 29 
(cost of service provision) (Table 2). This 
analysis focused on the short-term costs 
of guideline implementation (first year); 
it did not consider any possible cost 
savings resulting from future reductions 
in cardiovascular morbidity or mortality as 
it has been argued that such reductions 
would be minimal in this population.18
Analysis
Descriptive statistics were used to define 
the proportion of patients in each group with 
different levels of blood pressure control 
(normotension, stage 1, and stage 2–3 
hypertension). Data are presented according 
to age (40–54 years and 55–74 years) and 
sex; comparisons were made using c2 tests. 
The number of people with untreated, 
uncomplicated stage 1 hypertension 
in the population of England and Wales 
was estimated by extrapolating from the 
local prevalence estimates derived from 
this study to national population data.27 All 
data are presented as a mean, ± standard 
deviation (SD), and proportion of the total 
population with 95% confidence intervals 
(CIs) (unless otherwise stated). Costs were 
calculated in pounds sterling and converted 
to US dollars and euros for comparison 
purposes. All analyses were carried out 
using SPSS software (version 21).
RESULTS
Population characteristics
Of the 90 516 patients registered at 
participating practices, 34 975 were aged 
40–74 years and could have been included 
in this analysis; however, of these, 2550 
(7.3%) patients had existing CVD, 7406 
(21.2%) were already on treatment, and 
4764 (13.6%) had no clinic blood pressure 
readings in the preceding 5 years from 
the data extraction date. Of the remaining 
20 255 patients (57.9%), 4985 (14.3%) had 
total and HDL cholesterol information 
available to calculate CVD risk, leaving 15 
270 (43.7%) where cholesterol was imputed. 
Diabetes, chronic kidney disease, and 
ischaemic heart disease were the most 
common comorbidities (Table 3).
Prevalence of untreated, uncomplicated 
stage 1 hypertension
A total of 12 647 patients had hypertension, 
of which 4421 patients (35.0%) were not 
receiving antihypertensive treatment. In 
patients receiving no treatment, stage 1 
hypertension was present in 3321 individuals 
(9.5%, 95% CI = 9.2 to 9.8), of whom 2867 
(8.2%, 95% CI = 7.9 to 8.5) had low CVD 
risk (that is, ‘uncomplicated’). Untreated, 
uncomplicated stage 1 hypertension 
was more common in younger patients 
(1729 patients, 9.1%, 95% CI = 8.7 to 9.5 
[40–54 years] versus 1138 patients, 7.1%, 
95% CI = 6.7 to 7.5 [55–74 years], P<0.001) 
and females (1465 patients, 8.6%, 95% CI 
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Treated hypertension = patients prescribed antihypertensive therapy. Normotension = <140/90 mmHg. 
Untreated stage 1 hypertension = 140/90–159/99 mmHg. Untreated stage 2–3 hypertension = ≥160/100 mmHg. 
Prevalence of stage 1 hypertension was adjusted by a factor of 0.56 to account for the 56% positive predictive 
value of clinic BP measurements. All patients with a clinic BP of ≥160/100 mmHg were considered to have stage 
2 hypertension due to uncertainty about whether repeated measurement would affect classification at higher BP 
levels. BP = blood pressure. CVD = cardiovascular disease.
= 8.2 to 9.1 [females] versus 1402 patients, 
7.8%, 95% CI 7.4 to 8.2 [males], P=0.005), 
reflecting an increased risk of CVD in older 
patients and males. Figure 1 shows the 
prevalence of hypertension and risk by age 
and sex. CVD risk is well known to be higher 
in males and older people.34 
By applying these figures to national 
population estimates27 for people aged 
40–74 years, 1 892 519 patients in England 
and Wales (approximately 1 in 12 people) 
were estimated to have untreated, 
uncomplicated stage 1 hypertension.
Cost of treating uncomplicated stage 1 
hypertension
Based on the cost of a practice nurse 
measuring a patient’s blood pressure and 
delivering hypertension management 
(Table 2), the total cost of treating 
uncomplicated stage 1 hypertension in 
the sample population studied here was 
estimated to be £160 129 per year (Table 
4). Extrapolated to the national population 
of England and Wales, this figure rises to 
£106 million per year. If hypertension care 
was delivered by a GP, this figure would 
rise to £229 million per year (US$180–
389 million or €134–289 million) (Table 4).
DISCUSSION
Summary
This study shows that untreated, 
uncomplicated stage 1 hypertension 
is relatively common, affecting 1 in 12 
patients aged between 40–74 years in 
England and Wales. Assuming similar 
prevalence nationally, it was estimated that 
approximately 1.9 million people would 
be affected, with potential annual costs of 
antihypertensive treatment, if commenced, 
being £106–229 million (US$180–389million 
and €134–289 million). 
Initiation of therapy in such patients is 
not recommended (by guidelines) in the 
UK but many international guidelines do 
recommend therapy in this group,3–9,13 
despite little evidence to suggest it has any 
benefit.18 This study highlights that people 
with low risk stage 1 hypertension form a 
significant group for whom more robust 
evidence of cost-effectiveness is needed 
prior to commencement of antihypertensive 
treatment.
Strengths and limitations
This study used routine data from the West 
Midlands, UK, and included all registered 
patients aged 40–74 years from a large 
cohort of general practices. These data were 
comparable with the national population 
aged 35–74 years, in terms of mean age and 
sex,27 prevalence of stroke and ischaemic 
heart disease, diabetes, untreated 
hypertension,22 and mortality.39 It was not 
possible to compare the characteristics of 
the study population with national trends 
in ethnicity and social deprivation, and it 
is acknowledged that results extrapolated 
from local to national population data 
should be interpreted with caution.
Data used here were collected in 2008 
and 2009 but the researchers are confident 
that the prevalence estimates are still 
relevant today. According to figures from 
the Quality and Outcomes Framework 
(QOF),19 the prevalence of diagnosed 
hypertension in England has increased very 
slightly in the past 5 years (0.3%; from 
13.4% to 13.7%). The researchers would not 
anticipate treatment to have changed very 
much during this period, given that QOF 
targets have remained largely the same. 
Although NICE now recommends the use 
of ambulatory blood pressure monitoring 
in the diagnosis of hypertension,12 this 
was not expected to greatly influence the 
present results as prevalence estimates 
were adjusted to account for the accuracy 
(and variability) of clinic blood pressure 
used in isolation.33
The estimates of the prevalence 
of untreated, uncomplicated stage 1 
hypertension presented here may be 
conservative: patients without a blood 
pressure reading in the 5 years prior to the 
study were assumed to not have stage 1 
hypertension. Where it was recorded, no 
correction was made for blood pressure 
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Table 4. Costs of treating uncomplicated stage 1 hypertension across 
the sample and population of England and Wales, according to the 
health professional delivering treatment
Population  Cost, £a
Sample population,   Total, n 34 975 
  patients aged Untreated, uncomplicated stage 1 hypertension,b n 2867 
  40–74 years Total cost of treatment if delivered by practice nursec 160 129 
 Total cost of treatment if delivered by nurse specialistc 228 125 
 Total cost of treatment if delivered by GPd 347 117
Population of England Total population, n 23 284 217  
  and Wales, patients aged Untreated, uncomplicated stage 1 hypertension,b n 1 892 519 
  40–74 yearse Total cost of treatment if delivered by practice nursec 105 619 247 
 Total cost of treatment if delivered by nurse specialistc 150 500 331 
 Total cost of treatment if delivered by GPd 229 042 227
aUnless otherwise stated. bExcludes patients with these conditions for whom blood pressure was not measured 
within 5 years prior to the study being undertaken. cNurse appointment based on 15-minute consultation. dGP 
appointment based on 11.7-minute consultation. ePopulation in England and Wales is based on data from the 
Office for National Statistics, mid-year population estimates (2011).27 Drug costs from NHS Electronic Drug 
Tariff database, correct as of May 2013.28 Staff costs from Unit Costs of Health and Social Care 2012; unit costs 
based on the cost of face-to-face contact.29
measurement error in patients with stage 
2–3 hypertension due to uncertainty about 
the PPV of readings taken around the 
160/100 mmHg threshold. In practice, there 
is likely to be a degree of measurement 
error, resulting in some patients with stage 
1 hypertension being classed as having 
stage 2–3 hypertension and vice versa. The 
Framingham equation may overestimate 
risk, resulting in the misclassification of 
individuals (as high risk) and reducing our 
estimate of the prevalence of uncomplicated 
stage 1 hypertension;40 however, this tool 
was recommended for use in clinical 
practice by NICE at the time of data 
collection.35 
The assessments of CVD risk undertaken 
were limited to evaluating existing CVD and 
CVD risk score; target organ damage, and 
diabetes were not considered separately, 
although the latter was included in the 
Framingham risk equation used here.34 
Therefore, it is possible that a minority 
of patients may have been classified as 
low risk when, in practice, most would be 
treated as high risk. In the case of diabetes, 
however, only 211 patients were classified 
as low risk (1.0%), so the impact of any 
misclassification is likely to be relatively 
small. In addition, CVD risk was calculated 
using cholesterol readings, which were 
imputed in 15 270 patients. This represents 
a large proportion of the overall sample 
(44%) and there remains the possibility that 
such an approach may have affected the 
accuracy of risk estimates and, as such, 
also the overall estimates of untreated, 
uncomplicated stage 1 hypertension.
Finally, an assumption was made that 
there are no long-term benefits from 
the treatment of uncomplicated stage 1 
hypertension, in terms of potential cost 
savings based on the Cochrane Review 
findings.18 Should this assumption be 
incorrect, these results will underestimate 
potential benefit.
Comparison with existing literature
To the authors’ knowledge, this is the first 
study to document the community prevalence 
of untreated, uncomplicated stage 1 
hypertension anywhere in the world. The 
prevalence of hypertension in international 
surveys varies by method of diagnosis, 
and between countries and continents, 
from 23.0% to 46.0%20–24,41 (depending on 
the age range of the population studied); 
the lowest rates have been reported in 
Canada20 and the highest across Africa.23 
Estimates of untreated hypertension (12.6%) 
were comparable with those from previous 
surveys conducted in Australia (13.1%),24 
England (15.8%),22 and Japan (15.9%).26
Implications for research and practice
This study found that 1 in 12 patients aged 
40–74 years have untreated, uncomplicated 
stage 1 hypertension. The cost of a strategy 
to treat these patients in clinical practice 
was estimated to fall between £106 million 
and £229 million (US$180–389 million 
or €134–289 million). Whether to initiate 
treatment in patients with uncomplicated 
stage 1 hypertension is a source of much 
debate.14–17 The recent Cochrane Review 
by Diao et al,18 found no evidence that 
antihypertensive treatment in this 
population would result in reductions in 
mortality, coronary artery disease, stroke, or 
total CVD. Although both the authors of that 
review and subsequent commentators15 
point to a lack of power to show benefit, 
estimates of a number needed to treat (NNT) 
of 128 for 5 years per cardiovascular event 
averted suggest few people stand to gain 
from such treatment.18 Indeed, one previous 
study42 suggested that patients judge the 
maximum acceptable NNT for 5 years to 
prevent one death in hypertension to be 33 
— well below the putative NNT for CVD — 
rather than mortality benefit from treating 
uncomplicated stage 1 hypertension. 
Since the publication of the Cochrane 
Review,18 three guidelines for the 
management of hypertension have been 
published: 
• The Canadian Hypertension Education 
Program guidelines4 discounted the 
findings of the Cochrane Review 
because of the small sample size and 
cited a 35-year-old non-placebo trial43 
as justification for maintaining the 
recommendation to treat uncomplicated 
stage 1 hypertension (with the caveat that 
lifestyle modification may be sufficient 
to control blood pressure without the 
initiation of therapy).4
• The European Society of Hypertension 
(ESH) guidelines3 also note the lack of 
power in the Cochrane Review18 and 
highlight the paucity of evidence to guide 
therapy. However, taking into account 
the limited available evidence44 and the 
low cost and safety of antihypertensive 
agents, ESH recommends considering 
blood pressure-lowering therapy in this 
population. 
• The Eighth Joint National Committee 
guidelines13 revised thresholds for 
treatment such that patients aged 
≥60 years should be given treatment if 
their blood pressure is ≥150/90 mmHg. 
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In patients aged <60 years, initiation of 
treatment was encouraged at a threshold 
of 140/90 mmHg (regardless of risk), 
although it was acknowledged that this 
recommendation was based on expert 
opinion alone.
The data presented here do not suggest 
that therapy to reduce blood pressure 
in those with low CVD risk and stage 1 
hypertension would provide an adequate 
cost–benefit ratio, given the high NNT 
and costs in order to prevent one vascular 
event, along with the potential adverse 
consequences an individual may experience 
having been labelled as having hypertension 
through side effects and labelling.18,45,46
Untreated, uncomplicated stage 1 
hypertension is common, affecting at least 
8.2% of the population aged 40–74 years 
in England and Wales. International 
guidelines3–9,13 and pay-for-performance 
targets19 encouraging universal thresholds 
and treatment targets of <140/90 mmHg 
(regardless of underlying CVD risk) will lead 
to treatment, with little prospect of benefit 
at substantial financial cost to healthcare 
providers across the world. International 
recommendations should be re-examined 
to ensure evidence-based treatment until 
such time as new trials show that benefit 
outweighs harm and is cost effective.
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